Survodutide 10mg

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

Quickstart Highlights

Survodutide (BI 456906) is an investigational dual GLP-1 receptor / glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma for obesity and metabolic dysfunction-associated steatohepatitis (MASH)[1]. In clinical trials it is given as a once-weekly subcutaneous injection titrated upward over roughly 20 weeks. It is not approved by the FDA or EMA; it holds FDA Breakthrough Therapy Designation (2024) for non-cirrhotic MASH with fibrosis — an expedited-development status, not an approval — and is in Phase 3 trials. Presented for research and educational use only.

Add 2.0 mL bacteriostatic water to one 10 mg vial → ~5.0 mg/mL (5,000 mcg/mL). The 2.0 mL volume keeps higher weekly doses at or below 1.0 mL per injection.
600–4800 mcg once weekly, titrated upward gradually across a 16–24 week escalation anchored to clinical-trial ranges.
At ~5.0 mg/mL, 1 unit = 0.01 mL = 50 mcg on a U-100 syringe; 600 mcg = 12 units and 4800 mcg = 96 units.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F), protect from light and avoid freeze–thaw.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.

Dosing & Reconstitution Guide

A single practical dilution with accurate once-weekly dosing, step by step

Standard / Gradual Approach (2.0 mL = ~5.0 mg/mL)

Phase / Week(s)	Weekly Dose (per injection)	Volume (U-100 units / mL)
Weeks 1–4	600 mcg (1× weekly)	12 units (0.12 mL)
Weeks 5–8	1200 mcg (1× weekly)	24 units (0.24 mL)
Weeks 9–12	1800 mcg (1× weekly)	36 units (0.36 mL)
Weeks 13–16	2400 mcg (1× weekly)	48 units (0.48 mL)
Weeks 17–20 (optional)	3600 mcg (1× weekly)	72 units (0.72 mL)
Weeks 21–24 (optional)	4800 mcg (1× weekly)	96 units (0.96 mL)

Reconstitute: Add 2.0 mL bacteriostatic water to one 10 mg vial → final concentration ~5.0 mg/mL (5,000 mcg/mL).
Typical weekly range: 600–4800 mcg once weekly, raised gradually over a 16–24 week escalation.
Easy measuring: At ~5.0 mg/mL, 1 unit = 0.01 mL = 50 mcg on a U-100 syringe. Each weekly dose in micrograms divided by 50 gives the number of units.
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F), protect from light and avoid freeze–thaw of the mixed solution.
Frequency: one subcutaneous injection once weekly, titrating up as tolerated. The doses above are weekly per-injection amounts, not daily — this regimen is once weekly. Clinical trials escalated the weekly dose over roughly 20 weeks before maintenance; slower escalation can reduce gastrointestinal side effects such as nausea and diarrhea[2][3].

Reconstitution Steps

Draw 2.0 mL of bacteriostatic water into a sterile syringe.

Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
The 2.0 mL dilution is chosen so even the highest weekly doses stay at or below 1.0 mL per injection while keeping unit math simple. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptide.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Quantities below assume an 8–16 week course of once-weekly injections with gradual titration, anchored to clinical-trial dose ranges.

Totals are cumulative across the titration phases at one once-weekly dose per week.
8 weeks (0.6→1.2 mg): total ≈ 7.2 mg → 1 vial
12 weeks (adds 1.8 mg phase): total ≈ 14.4 mg → 2 vials
16 weeks (adds 2.4 mg phase): total ≈ 24.0 mg → 3 vials
Per week: 1 syringe (1 injection/week)
8 weeks: 8 syringes
12 weeks: 12 syringes
16 weeks: 16 syringes
Use ~2.0 mL per 10 mg vial for reconstitution.
8 weeks (1 vial): 2.0 mL → 1 bottle
12 weeks (2 vials): 4.0 mL → 1 bottle
16 weeks (3 vials): 6.0 mL → 1 bottle
One for the vial stopper + one for the injection site each dose.
Per week: 2 swabs
8 weeks: 16 swabs → 1 box
16 weeks: 32 swabs → 1 box

Protocol Overview

A concise summary of the once-weekly regimen, anchored to dose ranges used in Survodutide clinical trials.

▪Goal: Investigational dual GLP-1 / glucagon receptor activation studied for weight reduction and improvement of hepatic steatosis (MASH) — effects observed in clinical trials, not an approved indication[1].
▪Schedule: Once-weekly subcutaneous injections with stepwise escalation across roughly 16–24 weeks before maintenance.
▪Dose Range: 600–4800 mcg weekly (0.6–4.8 mg), escalating as tolerated within trial-tested ranges[2].
▪Reconstitution: 2.0 mL bacteriostatic water per 10 mg vial gives ~5.0 mg/mL, keeping higher weekly doses at or below 1.0 mL.
▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C, protect from light and avoid freeze–thaw.

Dosing Protocol

A suggested once-weekly titration approach informed by Survodutide clinical studies.

▪Start: Begin at 600 mcg once weekly to gauge tolerability.
▪Titrate: Increase by roughly 600 mcg every 4 weeks as tolerated (0.6 → 1.2 → 1.8 → 2.4 mg; optional 3.6 → 4.8 mg), mirroring the escalation used in trials[2][3].
▪Frequency: Once per week, subcutaneously.
▪Timing: Use a consistent weekly day and time, and rotate injection sites systematically.
▪Note: Slower escalation can mitigate GI adverse events such as nausea and diarrhea.

Storage Instructions

Correct storage is what preserves the peptide’s stability and activity.

▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[6].
▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F), protect from light and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[7].
▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.

Important Notes

Practical points that keep weekly administration safe and consistent.

▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[8].
▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow; do not aspirate for subcutaneous injections.
▪Manage GI effects: Nausea and diarrhea are the most common adverse events; a slower escalation and smaller, more frequent meals can help.
▪Regulatory note: Survodutide is not FDA- or EMA-approved for human use; it is investigational and presented here for research and educational purposes only.

How This Works

Survodutide (BI 456906) is an investigational dual agonist that activates both the GLP-1 receptor and the glucagon receptor, co-developed by Boehringer Ingelheim and Zealand Pharma[1].

GLP-1 receptor activation reduces appetite and slows gastric emptying, while glucagon receptor agonism is thought to raise energy expenditure and act on the liver to reduce hepatic fat (steatosis). Engaging both pathways is the rationale for studying it in obesity and in metabolic dysfunction-associated steatohepatitis (MASH)[4].
Phase 2 trials in obesity used once-weekly subcutaneous dosing with dose-dependent weight loss, and a Phase 2 MASH trial reported improvement in liver disease[2][5]. Phase 3 development is ongoing — SYNCHRONIZE in obesity and LIVERAGE in MASH.
Important caveat: Survodutide is not approved by the FDA or EMA. It holds FDA Breakthrough Therapy Designation (September 2024) for non-cirrhotic MASH with moderate-to-advanced fibrosis — an expedited-development status, not an approval. It remains investigational and is presented here for research and educational purposes only.

Lifestyle Factors

Habits that may support metabolic outcomes alongside the protocol.

▪Nutrition: Adopt a balanced, calorie-appropriate diet emphasizing protein and whole foods.
▪Activity: Combine resistance and aerobic training to reinforce metabolic adaptations and help preserve lean mass.
▪Sleep: Aim for 7–9 hours to support appetite regulation and overall metabolic health.
▪Hydration & adherence: Stay well hydrated and keep injections on a consistent weekly schedule to support tolerability.

Potential Benefits & Side Effects

Findings reported in Survodutide clinical trials; it remains investigational and individual results vary.

▪Weight reduction (clinical): Dose-dependent weight loss reported in Phase 2 obesity trials over a ~20-week escalation[2].
▪Liver outcomes (clinical): Phase 2 MASH data showed improvement in liver disease versus placebo[5].
▪Regulatory recognition: FDA Breakthrough Therapy Designation (2024) for non-cirrhotic MASH with fibrosis — an expedited status, not an approval[3].
▪Note on status: Survodutide is not approved and is still in Phase 3 trials; outcomes are not established for general use.
▪Gastrointestinal: Nausea, diarrhea and vomiting are the most common adverse events, typically dose-related and often easing with slower escalation.
▪Injection-site reactions: Mild redness or tenderness can occur; rotating sites helps.
▪Investigational profile: Long-term safety is still being characterized in ongoing Phase 3 trials.

Injection Technique

General subcutaneous technique, following established clinical best-practice guidance[9][10].

▪Wash your hands well with soap and water.
▪Wipe the vial stopper with an alcohol swab and let it air-dry.
▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[10].
▪Draw the intended weekly dose, then check for air bubbles and push any out.
▪Pinch a skinfold at the chosen site between thumb and forefinger.
▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[9].
▪Skip aspiration for subcutaneous shots — it isn’t needed[9].
▪Press the plunger slowly and steadily until it’s fully down.
▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
▪Return the reconstituted vial to the fridge right away.
▪Rotate the injection site each week to prevent irritation and lipohypertrophy[8].
▪Watch the site for excess redness, swelling, or signs of infection.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides.

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. Open source
▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Survodutide is investigational and may not be offered by every supplier. Product availability and specifications are subject to change — verify current product details on the supplier website.
Shop at Prime Lab Peptides →

References

Reference-derived details for Survodutide 10mg.

Survodutide (10mg Vial) Dosage Protocol Open source
1 New England Journal of Medicine Survodutide (BI 456906), a dual glucagon/GLP-1 receptor agonist: Phase 2 trial in people with overweight or obesity. View Source ↗ Open source
2 The Lancet Diabetes & Endocrinology Dose-finding Phase 2 study of survodutide with once-weekly subcutaneous dosing and dose-dependent weight loss. View Source ↗ Open source
3 U.S. Food & Drug Administration Breakthrough Therapy Designation for survodutide in non-cirrhotic MASH with moderate-to-advanced fibrosis (an expedited-development status, not an approval). View Source ↗ Open source
4 Molecular Metabolism (PubMed) Pharmacology of dual GLP-1/glucagon receptor agonism: appetite reduction, energy expenditure and hepatic fat. View Source ↗ Open source
5 New England Journal of Medicine Phase 2 trial of survodutide in metabolic dysfunction-associated steatohepatitis (MASH) showing improvement versus placebo. View Source ↗ Open source
6 Peptide Storage Guide Best practices for storing lyophilized peptides (temperature, humidity and light protection). View Source ↗ Open source
7 Bacteriostatic Water Guidance Bacteriostatic water for injection: multi-dose vial stability and handling. View Source ↗ Open source
8 NCBI Bookshelf Best practices for subcutaneous injection: aseptic technique and site rotation. View Source ↗ Open source
9 Centers for Disease Control and Prevention (CDC) Subcutaneous injection technique: angle, site and no-aspiration guidance. View Source ↗ Open source
10 Subcutaneous Injection Technique (Patient Education) How to administer a subcutaneous injection: clinical technique guidelines. View Source ↗ Open source
11 ClinicalTrials.gov Survodutide Phase 3 program registry entries (SYNCHRONIZE in obesity; LIVERAGE in MASH). View Source ↗ Open source

Contents